SCHEMBL9896522

SCHEMBL9896522

CCc1ccc(OCC2CC2)c(-c2ncnc3c(C(=O)N[C@H]4CC[C@H](NC(=O)CO)CC4)c(C)[nH]c23)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMYD3 Q9H7B4 2/20 0.34
BRD4 O60885 3/20 0.33
PDE5A O76074 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
RIPK2 O43353 1/20 0.33
HPGD P15428 2/20 0.33
GAA P10253 1/20 0.33
TSHR P16473 1/20 0.33
GRIN1 Q05586 3/20 0.32
GRIN2B Q13224 3/20 0.32
MAPK14 Q16539 2/20 0.32
PDE4A P27815 1/20 0.32
PDE4B Q07343 1/20 0.32
PDE4C Q08493 1/20 0.32
PDE4D Q08499 1/20 0.32
LMNA P02545 1/20 0.32
HSPB1 P04792 1/20 0.31
CYP2C9 P11712 1/20 0.31
MAPK11 Q15759 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9897406 1.00 SMYD3 (0.34) SMYD3BRD4PDE5AHDAC1HDAC6
SCHEMBL9896524 1.00 SMYD3 (0.34) SMYD3BRD4PDE5AHDAC1HDAC6
SCHEMBL9897226 0.94 PDE5A (0.35) SMYD3BRD4PDE5AHDAC1HDAC6
SCHEMBL9897170 0.94 PDE5A (0.35) SMYD3BRD4PDE5AHDAC1HDAC6
SCHEMBL9897168 0.94 PDE5A (0.35) SMYD3BRD4PDE5AHDAC1HDAC6
SCHEMBL9897518 0.93 LMNA (0.38) BRD4RIPK2HPGDGRIN1GRIN2B
SCHEMBL9895700 0.93 LMNA (0.38) BRD4RIPK2HPGDGRIN1GRIN2B
SCHEMBL9895698 0.93 LMNA (0.38) BRD4RIPK2HPGDGRIN1GRIN2B
SCHEMBL9897041 0.93 SMYD3 (0.36) SMYD3BRD4PDE5AHDAC1HDAC6
SCHEMBL1441884 0.93 SMYD3 (0.36) SMYD3BRD4PDE5AHDAC1HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2470536-B1 Methylpyrrolopyrimidinecarboxamides TAKEDA GMBH (DE) 2014-11-12 EP claimed
US-20120149721-A1 METHYLPYRROLOPYRIMIDINECARBOXAMIDES NYCOMED GMBH (DE) 2012-06-14 US claimed
US-9376442-B2 Methylpyrrolopyrimidinecarboxamides TAKEDA GMBH (DE) 2016-06-28 US disclosed
US-20150073001-A1 METHYLPYRROLOPYRIMIDINECARBOXAMIDES ASTRAZENECA AB (SE) 2015-03-12 US disclosed
US-8927557-B2 Methylpyrrolopyrimidinecarboxamides TAKEDA GMBH (DE) 2015-01-06 US disclosed
EP-2470536-B1 Methylpyrrolopyrimidinecarboxamides TAKEDA GMBH (DE) 2014-11-12 EP disclosed
US-20120149721-A1 METHYLPYRROLOPYRIMIDINECARBOXAMIDES NYCOMED GMBH (DE) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149721-A1 METHYLPYRROLOPYRIMIDINECARBOXAMIDES PDE5A, PDE12, PDE4A SMYD3 373/4885BRD4 575/4885PDE5A 1/4885
US-20150073001-A1 METHYLPYRROLOPYRIMIDINECARBOXAMIDES PDE12, PDE5A, PDE4A SMYD3 266/4885BRD4 435/4885PDE5A 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.